Molecular biology of gastric cancer

被引：53

作者：

Cervantes, A. ^{[1
]}

Braun, E. Rodriguez ^{[1
]}

Fidalgo, A. Perez ^{[1
]}

Gonzalez, I. Chirivella ^{[1
]}

机构：

[1] Univ Valencia, Hosp Clin Univ, Dept Hematol & Med Oncol, Fac Med & Odontol, Valencia 46010, Spain

来源：

CLINICAL & TRANSLATIONAL ONCOLOGY | 2007年 / 9卷 / 04期

基金：

美国国家卫生研究院;

关键词：

gastric cancer; molecular markers; genetic alterations; angiogenesis;

D O I：

10.1007/s12094-007-0041-4

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Despite its decreasing incidence overall, gastric cancer is still a challenging disease. Therapy is based mainly upon surgical resection when the tumour remains localised in the stomach. Conventional chemotherapy may play a role in treating micrometastatic disease and is effective as palliative therapy for recurrent or advanced disease. However, the knowledge of molecular pathways implicated in gastric cancer pathogenesis is still in its infancy and the contribution of molecular biology to the development of new targeted therapies in gastric cancer is far behind other more common cancers such as breast, colon or lung. This review will focus first on the difference of two well defined types of gastric cancer: intestinal and diffuse. A discussion of the cell of origin of gastric cancer with some intriguing data implicating bone marrow derived cells will follow, and a comprehensive review of different genetic alterations detected in gastric cancer, underlining those that may have clinical, therapeutic or prognostic implications.

引用

页码：208 / 215

页数：8

共 52 条

[1] Expression of metastasis-related genes in surgical specimens of human gastric cancer can predict disease recurrence [J].

Anzai, H ;

Kitadai, Y ;

Bucana, CD ;

Sanchez, R ;

Omoto, R ;

Fidler, IJ .

EUROPEAN JOURNAL OF CANCER, 1998, 34 (04) :558-565

[2]

Baffa R, 1998, CANCER RES, V58, P4708

[3]

Bevilacqua RAU, 2000, INT J CANCER, V87, P200, DOI 10.1002/1097-0215(20000715)87:2<200::AID-IJC7>3.0.CO

[4]

2-I

[5] Clinical uses of microsatellite instability testing in colorectal cancer: An ongoing challenge [J].

Boland, C. Richard .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (07) :754-756

[6] EXPRESSION OF P53 IN EARLY (T1) GASTRIC-CARCINOMA AND PRECANCEROUS ADJACENT MUCOSA [J].

BRITO, MJ ;

WILLIAMS, GT ;

THOMPSON, H ;

FILIPE, MI .

GUT, 1994, 35 (12) :1697-1700

[7]

Capuzzi D, 2000, CANCER, V88, P24, DOI 10.1002/(SICI)1097-0142(20000101)88:1<24::AID-CNCR5>3.3.CO

[8]

2-N

[9]

CHONG JM, 1994, CANCER RES, V54, P4595

[10] Loss of beta-catenin expression in metastatic gastric cancer [J].

Ebert, MPA ;

Yu, J ;

Hoffmann, J ;

Rocco, A ;

Röcken, C ;

Kahmann, S ;

Müller, O ;

Korc, M ;

Sung, JJ ;

Malfertheiner, P .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (09) :1708-1714

← 1 2 3 4 5 6 →